Press Release

Jan 9, 2023
Neuro2Go to offer the Alzheimer’s Risk Test

9th January 2023: We’re pleased to announce that Neuro2Go, an online neurology service that offers a convenient way to talk to a board-certified neurologist, will now offer the Alzheimer’s Risk Test, powered by genoSCORE™ to individuals who want to know their personal genetic risk for AD. 

Neuro2Go is a division of First Choice Neurology (FCN), one of the largest neurology practices in the US, which specialises in access to virtual, interactive video sessions with neurologists. This latest collaboration with Neuro2Go extends the use of the Alzheimer’s Risk Test beyond in-clinic practice and into telehealth. 

This collaboration extends the use of the Alzheimer’s Risk Test into telehealth, a fast-growing sector of the US healthcare market. More information at www.alzheimers-risk-test.com or schedule a NeuroChat at https://neuro2go.com/schedule-a-neurologist-virtual-visit/

During a virtual visit, Neuro2Go neurologists will assess those interested in understanding their risk of Alzheimer’s dementia and advise whether they are suitable for the test. Individuals wishing to proceed will receive a saliva collection device with pre-paid packaging so they can send their sample to the lab for analysis. The individual’s personal risk score will be explained during a second virtual visit. 

 

 

About Cytox (www.cytoxgroup.com)

Cytox Limited aims to enable everyone to know their personal risk for Alzheimer’s disease. Cytox supports two products in the market, powered by its genoSCORE™ Polygenic Risk Scoring technology. In the US, Cytox has partnered with Sampled Smart Labs which has developed the Alzheimer’s Risk Test, powered by genoSCORE™ (www.alzheimers-risk-test.com). In Europe Cytox, with its partner Yourgene Health, markets genoSCORE-LAB™ (www.genoscore-lab.com). 

About genoSCORE™

The genoSCORE™ technology is used to assess the genetic risk of cognitive decline due to Alzheimer’s disease (AD). The test, which uses a simple blood or saliva sample, analyses over 100,000 single nucleotide polymorphisms (SNPs) - small genetic variations - that are associated with AD. As such, the test generates a patient-specific polygenic risk score (PRS). Clinicians can use the test to assess patients for the risk of developing Alzheimer's, including before symptoms arise. In addition, the test can be used by developers of new AD drugs to identify individuals most likely to experience cognitive decline and/or respond to the therapy under investigation.

About Sampled and Sampled SMART Labs

Sampled is a next-generation laboratory that unlocks the valuable data in any biological sample to enable health innovators to improve human health. The integrated services offered by Sampled SMART Labs provide partners with a seamless solution for sample management and analysis. Sampled is headquartered in Piscataway, N.J. with labs across the US and Europe and partner labs in the Netherlands, China, and Australia. Infinity BiologiX LLC, Roylance Stability Storage Limited, and Roylance Scientific Limited are doing business as Sampled. For more information, visit www.sampled.com.

About Yourgene Health

Yourgene Health is an international molecular diagnostics group that develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science. Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US, and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com.